Please login to the form below

Not currently logged in
Email:
Password:

Anavex

This page shows the latest Anavex news and features for those working in and with pharma, biotech and healthcare.

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Clinical benefit correlated with increase in target biomarker SIGMAR1. Anavex Life Sciences’ investigational drug candidate ANAVEX2-73 led to improvements in clinical efficacy endpoints, including cognitive and non-cognitive measures, in

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...